Abstract：
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton\'s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
摘要：
近年来，慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的治疗前景得到了显着发展。布鲁顿酪氨酸激酶（BTK）抑制剂和BCL-2抑制剂的靶向治疗已成为先前未治疗或复发/难治性CLL/SLL患者的有效无化疗选择。治疗结束后无法检测到的微小残留疾病正在成为接受基于BCL-2抑制剂的固定持续时间治疗的患者的无进展和总生存期的重要预测指标。这些NCCN指南见解讨论了NCCNCLL/SLL指南的更新，该指南特定于针对初治和复发性/难治性疾病的患者使用无化疗治疗方案。
